Horizon Technology Finance Corp

Form 10-Q October 30, 2018

| UNITED STATES SECURITIES AND EXCHANGE COMMISSION |
|--|
| Washington, D.C. 20549 |
| |
| Form 10-Q |
| |
| (Mark One) |
| |
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2018 |
| OR |
| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
| FOR THE TRANSITION PERIOD FROMTO |
| COMMISSION FILE NUMBER: 814-00802 |

HORIZON TECHNOLOGY FINANCE CORPORATION

| | (Fract name | of registrant | as specified | in its | harter) |
|---|-------------|---------------|--------------|----------|---------|
| ı | Exaci name | oi regisirani | as specifiea | ını us o | manieri |

DELAWARE 27-2114934

(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

312 Farmington Avenue

Farmington, CT(Address of principal executive offices)

(Zip Code)

(860) 676-8654

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No "

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes "No"

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer " Accelerated filer x

Non-accelerated filer "Smaller reporting company"

Emerging growth company "

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes "No x

The number of shares of the registrant's common stock, \$0.001 par value per share, outstanding as of October 30, 2018 was 11,532,652.

HORIZON TECHNOLOGY FINANCE CORPORATION

FORM 10-Q

TABLE OF CONTENTS

| | | Page |
|----------------|--|-----------|
| | PART I | |
| <u>Item 1.</u> | Consolidated Financial Statements | <u>3</u> |
| | Consolidated Statements of Assets and Liabilities as of September 30, 2018 and December 31, 2017 (unaudited) | <u>3</u> |
| | Consolidated Statements of Operations for the three and nine months ended September 30, 2018 and 2017 (unaudited) | <u>4</u> |
| | Consolidated Statements of Changes in Net Assets for the nine months ended September 30, 2018 and 2017 (unaudited) | <u>5</u> |
| | Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and 2017 (unaudited) | <u>6</u> |
| | Consolidated Schedules of Investments as of September 30, 2018 and December 31, 2017 (unaudited) | <u>7</u> |
| | Notes to the Consolidated Financial Statements (unaudited) | <u>17</u> |
| | Management's Discussion and Analysis of Financial Condition and Results of Operations | <u>42</u> |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | <u>60</u> |
| <u>Item 4.</u> | Controls and Procedures | <u>60</u> |
| PART I | <u>I</u> | |
| Item 1. | Legal Proceedings | <u>62</u> |
| Item 1A. | Risk Factors | <u>62</u> |
| Item 2. | <u>Unregistered Sales of Equity Securities and Use of Proceeds</u> | <u>66</u> |
| Item 3. | Defaults Upon Senior Securities | <u>66</u> |
| Item 4. | Mine Safety Disclosures | <u>66</u> |
| <u>Item 5.</u> | Other Information | <u>66</u> |
| <u>Item 6.</u> | <u>Exhibits</u> | <u>66</u> |
| | <u>Signatures</u> | <u>67</u> |
| EX-31.1 | | |
| EX-31.2 | | |
| EX-32.1 | | |
| EX-32.2 | | |

PART I: FINANCIAL INFORMATION

Item 1. Consolidated Financial Statements

Horizon Technology Finance Corporation and Subsidiaries

Consolidated Statements of Assets and Liabilities (Unaudited)

(Dollars in thousands, except share and per share data)

| | September 30, 2018 | December 31, 2017 |
|--|--------------------|-------------------|
| Assets | | |
| Non-affiliate investments at fair value (cost of \$228,313 and \$219,303, respectively) | \$ 227,813 | \$ 218,600 |
| Non-controlled affiliate investments at fair value (cost of \$7,882 and \$3,774, respectively) (Note 5) | 7,531 | 3,499 |
| Controlled affiliate investments at fair value (cost of \$4,413 and \$0, respectively) (Note 5) | 4,413 | _ |
| Total investments at fair value (cost of \$240,608 and \$223,077, respectively) (Note 4) | 239,757 | 222,099 |
| Cash | 5,909 | 6,594 |
| Interest receivable | 4,765 | 3,986 |
| Other assets | 1,731 | 1,467 |
| Total assets | \$ 252,162 | \$ 234,146 |
| Liabilities | | |
| Borrowings (Note 7) | \$ 112,284 | \$ 94,075 |
| Distributions payable | 3,459 | 3,456 |
| Base management fee payable (Note 3) | 410 | 379 |
| Incentive fee payable (Note 3) | 851 | 541 |
| Other accrued expenses | 702 | 620 |
| Total liabilities | 117,706 | 99,071 |
| Commitments and Contingencies (Note 8) | | |
| Net assets | | |
| Preferred stock, par value \$0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of September 30, 2018 and December 31, 2017 | _ | _ |
| | 12 | 12 |

Common stock, par value \$0.001 per share, 100,000,000 shares authorized, 11,698,864 and 11,687,871 shares issued and 11,531,399 and 11,520,406 shares outstanding as of September 30, 2018 and December 31, 2017, respectively Paid-in capital in excess of par 179,606 179,641 Distributions in excess of net investment income (1,898)(2,372)) Net unrealized depreciation on investments (851) (978) Net realized loss on investments (41,939) (41,702) Total net assets 134,456 135,075 Total liabilities and net assets \$ 252,162 \$ 234,146 Net asset value per common share \$ 11.66 \$ 11.72

See Notes to Consolidated Financial Statements

Consolidated Statements of Operations (Unaudited)

(Dollars in thousands, except share and per share data)

| | For the Three September 3 | ee Months Ended | For the Nin September | ne Months Ended 30, |
|--|---------------------------|-----------------|--------------------------|---------------------|
| | 2018 | 2017 | 2018 | 2017 |
| Investment income | | | | |
| Interest income on investments | | | | |
| Interest income on non-affiliate investments | \$7,094 | \$6,164 | \$20,385 | \$17,861 |
| Interest income on non-controlled affiliate investments | 193 | 81 | 528 | 81 |
| Total interest income on investments | 7,287 | 6,245 | 20,913 | 17,942 |
| Fee income | | | | |
| Prepayment fee income on non-affiliate investments | 102 | 399 | 414 | 1,187 |
| Fee income on non-affiliate investments | 325 | 130 | 875 | 485 |
| Total fee income | 427 | 529 | 1,289 | 1,672 |
| Dividend income | | | | |
| Dividend income on affiliate investments | 83 | _ | 83 | _ |
| Total dividend income | 83 | _ | 83 | _ |
| Total investment income | 7,797 | 6,774 | 22,285 | 19,614 |
| Expenses | | | | |
| Interest expense | 1,681 | 1,140 | 4,616 | 3,540 |
| Base management fee (Note 3) | 1,197 | 921 | 3,399 | 2,783 |
| Performance based incentive fee (Note 3) | 1,297 | 258 | 2,823 | 1,094 |
| Administrative fee (Note 3) | 162 | 194 | 517 | 575 |
| Professional fees | 289 | 275 | 997 | 1,105 |
| General and administrative | 215 | 189 | 636 | 600 |
| Total expenses | 4,841 | 2,977 | 12,988 | 9,697 |
| Performance based incentive fee waived (Note 3) | (446 |) — | (605 |) — |
| Net expenses | 4,395 | 2,977 | 12,383 | 9,697 |
| Net investment income | 3,402 | 3,797 | 9,902 | 9,917 |
| Net realized and unrealized gain (loss) on investments | | | | |
| Net realized gain (loss) on non-affiliate investments | 66 | (429 |) (237 |) (11,098) |
| Net realized gain (loss) on investments | 66 | (429 |) (237 |) (11,098) |
| Net unrealized appreciation (depreciation) on non-affiliate investments | 761 | (640 |) 202 | 8,295 |
| Net unrealized appreciation (depreciation) on non-controlled affiliate investments | 30 | (19 |) (75 |) (19) |
| Net unrealized appreciation (depreciation) on investments | 791 | (659 |) 127 | 8,276 |
| Net realized and unrealized gain (loss) on investments | 857 | (1,088 |) (110 |) (2,822) |
| Net increase in net assets resulting from operations | \$4,259 | \$2,709 | \$9,792 | \$7,095 |

| Net investment income per common share | \$0.30 | \$0.33 | \$0.86 | \$0.86 |
|---|------------|------------|------------|------------|
| Net increase in net assets per common share | \$0.37 | \$0.24 | \$0.85 | \$0.62 |
| Distributions declared per share | \$0.30 | \$0.30 | \$0.90 | \$0.90 |
| Weighted average shares outstanding | 11,529,611 | 11,518,552 | 11,525,906 | 11,516,246 |

See Notes to Consolidated Financial Statements

Consolidated Statements of Changes in Net Assets (Unaudited)

(Dollars in thousands, except share data)

| | | | | Distribution | ns | | |
|---|------------|-------|---------------|-----------------|--------------------------|-----------------|-------------|
| | | | Paid-In | | Net | N T 4 | |
| | Common Sto | ck | Capital in | in Excess of | Unrealized Depreciation | Net Realized | Total Net |
| | | | | Net | - | Loss on | |
| | | | Excess of | Investment | on | | |
| | Shares | Amour | ntPar | Income | Investments | Investment | ts Assets |
| Balance at December 31, 2016 | 11,510,424 | \$ 12 | \$179,551 | \$ (397 |) \$ (19,463 | \$ (20,511) |) \$139,192 |
| Net increase in net assets resulting from operations | _ | _ | _ | 9,917 | 8,276 | (11,098 |) 7,095 |
| Issuance of common stock under dividend reinvestment plan | 12,278 | _ | 134 | _ | _ | _ | 134 |
| Repurchases of common stock | (5,923) | _ | (59) | _ | _ | _ | (59) |
| Distributions declared | | _ | _ | (10,366 |) — | _ | (10,366) |
| Balance at September 30, 2017 | 11,516,779 | \$ 12 | \$179,626 | \$ (846 |) \$ (11,187 | \$ (31,609) |) \$135,996 |
| Balance at December 31, 2017 | 11,520,406 | \$ 12 | \$179,641 | \$ (1,898 |) \$ (978 |) \$ (41,702 |) \$135,075 |
| Net increase in net assets resulting from operations | _ | _ | _ | 9,902 | 127 | (237 |) 9,792 |
| Financing costs | _ | _ | (155) | _ | _ | _ | (155) |
| Issuance of common stock under dividend reinvestment plan | 10,993 | _ | 120 | _ | _ | _ | 120 |
| Distributions declared | _ | | _ | (10,376 |) — | _ | (10,376) |
| Balance at September 30, 2018 | 11,531,399 | \$ 12 | \$179,606 | \$ (2,372 |) \$ (851 |) \$ (41,939 |) \$134,456 |

See Notes to Consolidated Financial Statements

Consolidated Statements of Cash Flows (Unaudited)

| | For the Nir September 2018 | 30, | onths Ende | d |
|--|--|-------|---|-----|
| Cash flows from operating activities: Net increase in net assets resulting from operations Adjustments to reconcile net increase in net assets resulting from operations to net cash (used in) provided by operating activities: | \$ 9,792 | | \$ 7,095 | |
| Amortization of debt issuance costs Net realized loss on investments Net unrealized appreciation on investments Purchase of investments Principal payments received on investments Investments in controlled affiliate investments Proceeds from sale of investments Equity received in settlement of fee income Warrants received in settlement of fee income Changes in assets and liabilities: | 420 237 (127 (62,246 46,503 (4,413 3,360 (299 (161 |))) | 383 11,098 (8,276 (66,311 80,062 — 1,572 — |) |
| (Increase) decrease in interest receivable (Increase) decrease in end-of-term payments Decrease in unearned income Decrease in other assets Increase in other accrued expenses Increase (decrease) in base management fee payable | (48 (731 (512 72 82 31 |)) | 253 1,008 (437 423 22 (33 |) |
| Increase in incentive fee payable Net cash (used in) provided by operating activities Cash flows from financing activities: Proceeds from issuance of 2022 Notes Advances on credit facility Repayment of credit facility Distributions paid Repurchase of common stock | 310 (7,730 — 28,000 (10,000 (10,253 — |)) | 258 27,117 32,500 34,000 (97,000 (10,230 (59 |) |
| Debt issuance costs Financing costs Net cash provided by (used in) financing activities Net decrease in cash Cash: Beginning of period End of period | (547 (155 7,045 (685 6,594 \$ 5,909 |)) | (1,137 — (41,926 (14,809 37,135 \$ 22,326 |)) |

Supplemental disclosure of cash flow information:

| 11 | | |
|--|----------|----------|
| Cash paid for interest | \$ 4,085 | \$ 3,242 |
| Supplemental non-cash investing and financing activities: | | |
| Warrant investments received and recorded as unearned income | \$ 1,007 | \$ 1,482 |
| Distributions payable | \$ 3,459 | \$ 3,455 |
| End-of-term payments receivable | \$ 3,667 | \$ 3,657 |
| Receivable resulting from sale of investment | \$ 59 | \$ — |

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

September 30, 2018

| | | | Principal | Cost of Investments | Fair |
|--|------------------|---|-----------|---------------------|---------|
| Portfolio Company (1)(3) | Sector | Type of Investment $(4)(7)(9)(10)$ | Amount | (6) | Value |
| Non-Affiliate Investments – Non-Affiliate Debt Investments – Non-Affiliate Debt Investment | ents — 155.1% (8 | | | | |
| Celsion Corporation (2)(5)(12) | Biotechnology | Term Loan (9.73% cash (Libor + 7.63%; Floor 9.63%), 4.00% ETP, Due 7/1/22) | \$ 2,500 | \$ 2,446 | \$2,446 |
| | | Term Loan (9.73% cash (Libor + 7.63%; Floor | 2,500 | 2,446 | 2,446 |
| | | 9.63%), 4.00% ETP, Due 7/1/22) Term Loan (9.73% cash (Libor + 7.63%; Floor | 2,500 | 2,446 | 2,446 |
| | | 9.63%), 4.00% ETP, Due 7/1/22) Term Loan (9.73% cash (Libor + 7.63%; Floor 9.63%), 4.00% ETP, Due 7/1/22) | 2,500 | 2,446 | 2,446 |
| Espero BioPharma, Inc. (2)(12) | Biotechnology | Term Loan (12.00% cash (Libor + 9.9%; Floor 12.00%), 4.00% ETP, Due | 5,000 | 4,689 | 4,689 |
| Palatin Technologies, Inc. (2)(5)(12) | Biotechnology | 6/30/19) Term Loan (10.60% cash (Libor + 8.50%; Floor 9.00%), 5.00% ETP, Due 1/1/19) | 500 | 495 | 495 |
| | | Term Loan (10.60% cash (Libor + 8.50%; Floor | 500 | 500 | 500 |
| | | 9.00%), 3.44% ETP, Due 1/1/19) Term Loan (10.60% cash (Libor + 8.50%; Floor 9.00%), 5.00% ETP, Due 8/1/19) | 1,667 | 1,652 | 1,652 |
| | | Term Loan (10.60% cash (Libor + 8.50%; Floor | 1,667 | 1,667 | 1,667 |
| vTv Therapeutics Inc. (2)(5)(12) | Biotechnology | 9.00%), 3.27% ETP, Due 8/1/19) Term Loan (12.10% cash (Libor + 10.00%; Floor | 4,948 | 4,912 | 4,912 |

| | | 10.50%), 6.00% ETP, Due 5/1/20) Term Loan (12.10% cash (Libor + 10.00%; Floor 10.50%), 6.00% ETP, Due 10/1/20) | 3,750 | 3,714 | 3,714 |
|---|----------------|--|-------|--------|--------|
| Titan Pharmaceuticals, Inc. (2)(5)(12) | Drug Delivery | Term Loan (10.50% cash (Libor + 8.40%; Floor 9.50%), 5.00% ETP, Due 6/1/21) | 1,600 | 1,484 | 1,484 |
| Aerin Medical, Inc. (2)(12) | Medical Device | Term Loan (9.55% cash (Libor + 7.45%; Floor 8.75%), 4.00% ETP, Due 1/1/22) | 4,000 | 3,887 | 3,887 |
| | | Term Loan (9.55% cash (Libor + 7.45%; Floor 8.75%), 4.00% ETP, Due 1/1/22) | 3,000 | 2,963 | 2,963 |
| | | Term Loan (9.55% cash (Libor + 7.45%; Floor 8.75%), 4.00% ETP, Due 1/1/22) | 3,000 | 2,963 | 2,963 |
| Conventus Orthopaedics, Inc. (2)(12) | Medical Device | Term Loan (10.10% cash (Libor + 8.00%; Floor 9.25%), 6.00% ETP, Due 6/1/21) | 4,000 | 3,944 | 3,944 |
| | | Term Loan (10.10% cash (Libor + 8.00%; Floor 9.25%), 6.00% ETP, Due 6/1/21) | 4,000 | 3,944 | 3,944 |
| | | Term Loan (10.10% cash (Libor + 8.00%; Floor 9.25%), 6.00% ETP, Due 6/1/21) | 4,000 | 3,944 | 3,944 |
| CSA Medical, Inc. (12) | Medical Device | Term Loan (10.14% cash (Libor + 7.93%; Floor 10.00%), 5.00% ETP, Due | 6,000 | 5,761 | 5,761 |
| Lantos Technologies, Inc. (2)(12) | Medical Device | 10/1/22) Term Loan (10.53% cash (Libor + 8.43%; Floor 10.00%), 6.00% ETP, Due | 4,000 | 3,522 | 3,522 |
| MacuLogix, Inc. (2)(12) | Medical Device | 9/1/21) Term Loan (9.78% cash (Libor + 7.68%; Floor 9.50%), 4.00% ETP, Due 8/1/22) | 3,750 | 3,525 | 3,525 |
| VERO Biotech LLC (2)(12) | Medical Device | Term Loan (10.10% cash (Libor + 8.00%; Floor 9.25%), 5.00% ETP, Due 1/1/22) | 4,000 | 3,946 | 3,946 |
| | | Term Loan (10.10% cash (Libor + 8.00%; Floor 9.25%), 5.00% ETP, Due 1/1/22) | 4,000 | 3,946 | 3,946 |
| Total Non-Affiliate Debt Inv Non-Affiliate Debt Investme | | Science | | 71,242 | 71,242 |
| Audacy Corporation (2)(12) | | Term Loan (10 00% cash (Libor | 4,000 | 3,932 | 3,932 |
| Intelepeer Holdings, Inc. (2)(12) | Communications | 9.50%), 5.00% ETP, Due 7/1/22) Term Loan (12.05% cash (Libor + 9.95%; Floor | 4,000 | 3,942 | 3,942 |

Edgar Filing: Horizon Technology Finance Corp - Form 10-Q

| | | 11.25%), 2.50% ETP, Due 7/1/21) Term Loan (12.05% cash (Libor + 9.95%; Floor | 4,000 | 3,942 | 3,942 |
|---------------------------|----------------|--|-------|-------|-------|
| | | 11.25%), 2.50% ETP, Due 7/1/21) Term Loan (12.05% cash (Libor + 9.95%; Floor 11.25%), 2.50% ETP, Due | 4,000 | 3,942 | 3,942 |
| | | 7/1/21) Term Loan (12.05% cash (Libor + 9.95%; Floor 11.25%), 2.50% ETP, Due | 3,000 | 2,952 | 2,952 |
| PebblePost, Inc. (2) (12) | Communications | 2/1/22) Term Loan (11.36% cash (Libor + 9.26%; Floor 10.25%), 4.00% ETP, Due 7/1/21) | 4,000 | 3,947 | 3,947 |

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

September 30, 2018

| | | | Principal | | Fair |
|------------------------------------|-----------------------|---|-----------|-----------------|-------|
| Portfolio Company (1)(3) | Sector | Type of Investment $(4)(7)(9)(10)$ | Amount | Investments (6) | Value |
| | | Term Loan (11.36% cash (Libor + 9.26%; Floor | 4,000 | 3,947 | 3,947 |
| IgnitionOne, Inc. (2)(12) | Internet and Media | 10.25%), 4.00% ETP, Due 7/1/21) Term Loan (12.33% cash (Libor + 10.23%; Floor 10.23%), 2.00% ETP, Due 4/1/22) | 3,000 | 2,861 | 2,861 |
| | | Term Loan (12.33% cash (Libor + 10.23%; Floor | 3,000 | 2,861 | 2,861 |
| | | 10.23%), 2.00% ETP, Due 4/1/22) Term Loan (12.33% cash (Libor + 10.23%; Floor | 3,000 | 2,861 | 2,861 |
| | | 10.23%), 2.00% ETP, Due 4/1/22) Term Loan (12.33% cash (Libor + 10.23%; Floor | 3,000 | 2,861 | 2,861 |
| Jump Ramp Games, Inc. (2)(12) | Internet and Media | 10.23%), 2.00% ETP, Due 4/1/22) Term Loan (11.83% cash (Libor + 9.73%), | 4,000 | 3,956 | 3,851 |
| Kixeye, Inc. (2)(12) | Internet and Media | 3.00% ETP, Due 4/1/21) Term Loan (11.70% cash (Libor + 9.60%; Floor | 2,750 | 2,658 | 2,658 |
| | | 10.75%), 2.00% ETP, Due 5/1/21) Term Loan (11.70% cash (Libor + 9.60%; Floor | 2,750 | 2,707 | 2,707 |
| Rocket Lawyer Incorporated (2)(12) | Internet and Media | 10.75%), 2.00% ETP, Due 5/1/21) Term Loan (11.50% cash (Libor + 9.40%; Floor | 4,000 | 3,947 | 3,947 |
| | | 10.50%), 3.00% ETP, Due 7/1/21) Term Loan (11.50% cash (Libor + 9.40%; Floor | 4,000 | 3,947 | 3,947 |
| | | 10.50%), 3.00% ETP, Due 7/1/21) Term Loan (11.50% cash (Libor + 9.40%; Floor | 2,000 | 1,971 | 1,971 |

| | | 10.50%), 3.00% ETP, Due 11/1/21) | | | |
|-------------------------------------|-----------------------|--|-------|-------|-------|
| Verve Wireless, Inc. (2)(12) | Internet and Media | Term Loan (10.90% cash (Libor + 8.80%; Floor 10.80%), 3.33% ETP, Due 9/1/21) | 3,600 | 3,460 | 3,460 |
| Zinio Holdings, LLC (2)(12) | Internet and Media | Term Loan (13.35% cash (Libor + 11.25%; Floor 11.75%), 6.00% ETP, Due 2/1/20) | 3,400 | 3,386 | 3,386 |
| The NanoSteel Company, Inc. (2)(12) | Materials | Term Loan (11.60% cash (Libor + 9.50%; Floor | 3,959 | 3,891 | 3,891 |
| | | 10.00%), 7.20% ETP, Due 5/1/20) Term Loan (11.60% cash (Libor + 9.50%; Floor | 1,980 | 1,955 | 1,955 |
| | | 10.00%), 6.45% ETP, Due 5/1/20) Term Loan (11.60% cash (Libor + 9.50%; Floor 10.00%), 5.85% ETP, Due 7/1/20) | 2,188 | 2,159 | 2,159 |
| Powerhouse Dynamics, Inc. (2)(12) | Power Management | Term Loan (12.80% cash (Libor + 10.70%; Floor 11.20%), 3.32% ETP, Due 9/1/19) | 700 | 682 | 682 |
| Luxtera, Inc. (12) | Semiconductors | Term Loan (12.00% cash (Prime + 6.75%), Due 3/28/20) | 2,000 | 1,934 | 1,934 |
| | | Term Loan (12.00% cash (Prime + 6.75%), Due 3/28/20) | 1,500 | 1,462 | 1,462 |
| Bridge2 Solutions, LLC. (2)(12) | Software | Term Loan (11.35% cash (Libor + 9.25%; Floor 10.50%), 2.00% ETP, Due | 5,000 | 4,821 | 4,821 |
| | | 11/1/21) Term Loan (11.35% cash (Libor + 9.25%; Floor 10.50%), 2.00% ETP, Due | 5,000 | 4,821 | 4,821 |
| Education Elements, Inc. (2)(12) | Software | 11/1/21) Term Loan (12.10% cash (Libor + 10.00%; Floor 10.50%), 4.00% ETP, Due 1/1/19) | 200 | 197 | 197 |
| | | Term Loan (12.10% cash (Libor + 10.00%; Floor 10.50%), 4.00% ETP, Due 8/1/19) | 500 | 493 | 493 |
| New Signature US, Inc. (2)(12)(13) | Software | Term Loan (10.60% cash (Libor + 8.50%; Floor 10.50%), 3.50% ETP, Due 7/1/22) | 2,750 | 2,697 | 2,697 |
| ShopKeep.com, Inc. (2)(12) | Software | Term Loan (12.05% cash (Libor + 9.95%; Floor 10.45%), 4.08% ETP, Due | 4,900 | 4,825 | 4,825 |
| | | 10/1/20) Term Loan (12.05% cash (Libor + 9.95%; Floor | 3,600 | 3,542 | 3,542 |
| SIGNiX, Inc. (12) | Software | 10.45%), 3.55% ETP, Due 2/1/21) | 1,995 | 1,927 | 1,605 |

Edgar Filing: Horizon Technology Finance Corp - Form 10-Q

| xAd, Inc. (2)(12) | Software | Term Loan (13.10% cash (Libor + 11.00%; Floor 11.50%), 6.17% ETP, Due 2/1/20) Term Loan (10.80% cash (Libor + 8.70%; Floor 10.00%), 4.75% ETP, Due 11/1/21) | 5,000 | 4,916 | 4,916 |
|-------------------|----------|---|-------|-------|-------|
| | | Term Loan (10.80% cash (Libor + 8.70%; Floor 10.00%), 4.75% ETP, Due | 5,000 | 4,916 | 4,916 |
| | | 11/1/21) Term Loan (10.80% cash (Libor + 8.70%; Floor 10.00%), 4.75% ETP, Due | 3,000 | 2,950 | 2,950 |
| | | 11/1/21) Term Loan (10.80% cash (Libor + 8.70%; Floor | 2,000 | 1,966 | 1,966 |

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

September 30, 2018

| Portfolio Company (1)(3) | Sector | Type of Investment | Principal Amount | Investments | Fair Value |
|---|--------------------------|---|---------------------|-------------|---------------|
| | | (4)(7)(9)(10) 10.00%), 4.75% ETP, Due 11/1/21) | | (6) | |
| Total Non-Affiliate Debt Inv Non-Affiliate Debt Investment | | , | % (8) | 114,234 | 113,807 |
| Catasys, Inc. (2)(5)(12) | Software | Term Loan (9.85% cash (Libor + 7.75%; Floor 9.75%), 6.00% | 2,500 | 2,477 | 2,477 |
| | | ETP, Due 3/1/22) Term Loan (9.85% cash (Libor + 7.75%; | 2,500 | 2,477 | 2,477 |
| | | Floor 9.75%), 6.00% ETP, Due 3/1/22) Term Loan (9.85% cash | 2,500 | 2,476 | 2,476 |
| | | (Libor + 7.75%; Floor 9.75%), 6.00% ETP, Due 3/1/22) | 2,300 | 2,470 | 2,470 |
| HealthEdge Software, Inc. (2)(12) | Software | Term Loan (10.35% cash (Libor + 8.25%; Floor 9.25%), 3.00% | 5,000 | 4,905 | 4,905 |
| | | ETP, Due 7/1/22) Term Loan (10.35% cash (Libor + 8.25%; | 3,750 | 3,701 | 3,701 |
| | | Floor 9.25%), 3.00% ETP, Due 1/1/23) Term Loan (10.35% cash (Libor + 8.25%; Floor 9.25%), 3.00% | 3,750 | 3,698 | 3,698 |
| | | ETP, Due 4/1/23) Term Loan (10.46% cash (Libor + 8.25%; | 3,750 | 3,696 | 3,696 |
| Total Non-Affiliate Debt In | vestments — Healthcare i | Floor 9.25%), 3.00% ETP, Due 10/1/23) information and services | | 23,430 | 23,430 |

| Total Non- Affiliate Debt In | vestments | | 208,906 | 208,479 |
|---|----------------|---------------------------------------|---------|---------|
| Non-Affiliate Warrant Inves Non-Affiliate Warrants — L | | | | |
| ACT Biotech Corporation | Biotechnology | 130,872 Preferred Stock Warrants | 12 | _ |
| Alpine Immune Sciences, Inc. (5)(12) | Biotechnology | 4,634 Common Stock Warrants | 122 | _ |
| Argos Therapeutics, Inc. (2)(5)(12) | Biotechnology | 3,656 Common Stock Warrants | 33 | _ |
| Celsion Corporation (2)(5)(12) | Biotechnology | 190,522 Common Stock Warrants | 145 | 107 |
| Espero BioPharma, Inc. (2)(5)(12) | Biotechnology | 833,792 Common Stock Warrants | 184 | 184 |
| Rocket Pharmaceuticals Corporation (5)(12) | Biotechnology | 1,763 Common Stock Warrants | 17 | _ |
| Palatin Technologies, Inc. (2)(5)(12) | Biotechnology | 608,058 Common Stock Warrants | 51 | 153 |
| Revance Therapeutics, Inc. (5)(12) | Biotechnology | 34,113 Common Stock Warrants | 68 | 367 |
| Sample6, Inc. (2)(12) | Biotechnology | 661,956 Preferred Stock Warrants | 53 | 26 |
| Strongbridge U.S. Inc. (2)(5)(12) | Biotechnology | 160,714 Common Stock Warrants | 72 | 419 |
| Sunesis Pharmaceuticals, Inc. (5)(12) | Biotechnology | 2,050 Common Stock Warrants | 5 | _ |
| vTv Therapeutics Inc. (2)(5)(12) | Biotechnology | 95,293 Common Stock Warrants | 44 | _ |
| Titan Pharmaceuticals, Inc. (2)(5)(12) | Drug Delivery | 320,612 Common Stock Warrants | 95 | _ |
| AccuVein Inc. (2)(12) | Medical Device | 1,174,881 Preferred Stock Warrants | 24 | 29 |
| Aerin Medical, Inc. (2)(12) | Medical Device | 1,818,182 Preferred Stock Warrants | 66 | 71 |
| Conventus Orthopaedics, Inc. (2)(12) | Medical Device | 720,000 Preferred Stock Warrants | 95 | 102 |
| CSA Medical, Inc. (12) | Medical Device | 1,569,577 Preferred Stock Warrants | 89 | 89 |
| Lantos Technologies, Inc. (2)(12) | Medical Device | 1,715,926 Common Stock Warrants | 253 | 285 |
| MacuLogix, Inc. (2)(12) | Medical Device | 158,451 Preferred Stock Warrants | 156 | 156 |
| Mitralign, Inc. (2)(12) | Medical Device | 64,190 Common Stock Warrants | 52 | 1 |
| NinePoint Medical, Inc. (2)(12) | Medical Device | 29,102 Preferred Stock Warrants | 33 | _ |
| ReShape Lifesciences Inc. (5)(12) | Medical Device | 134 Common Stock Warrants | 347 | _ |
| Tryton Medical, Inc. (2)(12) | Medical Device | 122,362 Preferred Stock Warrants | 15 | 13 |
| VERO Biotech LLC (2)(12) | Medical Device | | 53 | 334 |

| ViOptix, Inc. (12) Total Non-Affiliate Warrants Non-Affiliate Warrants — Te | | 800 Common Stock Warrants 375,763 Preferred Stock Warrants | 13 2,097 | |
|---|-------------------------------|---|-------------|-----|
| Audacy Corporation (2)(12) | | 1,017,173 Preferred Stock Warrants | 194 | 195 |
| Ekahau, Inc. (2)(12) | Communications | 978,261 Preferred Stock Warrants | 33 | 899 |
| Intelepeer Holdings, Inc. (2)(12) | Communications | 2,451,549 Preferred Stock Warrants | 160 | 128 |
| PebblePost, Inc. (2)(12) | Communications | 598,850 Preferred Stock Warrants | 92 | 163 |
| Additech, Inc. (2)(12) | Consumer-related Technologies | 150,000 Preferred Stock Warrants | 32 | _ |
| Gwynnie Bee, Inc. (2)(12) | Consumer-related Technologies | 268,591 Preferred Stock Warrants | 68 | 823 |
| Le Tote, Inc. (2)(12) | Consumer-related Technologies | 202,974 Preferred Stock Warrants | 63 | 373 |
| Rhapsody International Inc. (2)(12) | Consumer-related Technologies | 852,273 Common Stock Warrants | 164 | _ |
| IgnitionOne, Inc. (2)(12) | Internet and Media | 262,910 Preferred Stock Warrants | 672 | 666 |
| Jump Ramp Games, Inc. (2)(12) | Internet and Media | 159,766 Preferred Stock Warrants | 32 | 8 |
| Kixeye, Inc. (2)(12) | Internet and Media | 791,251 Preferred Stock Warrants | 75 | 62 |
| Rocket Lawyer Incorporated (2)(12) | Internet and Media | 261,721 Preferred Stock Warrants | 92 | 78 |
| Verve Wireless, Inc. (2)(12) | Internet and Media | 112,805 Common Stock Warrants | 120 | 120 |

See Notes to Consolidated Financial Statements

Consolidated Schedule of Investments (Unaudited)

September 30, 2018

| Portfolio Company (1)(3) | Sector | Type of Investment (4)(7)(9)(10) | PrincipalCost of Amount Investments (6) | Fair Value |
|--|---------------------|---------------------------------------|---|---------------|
| The NanoSteel Company, Inc. (2)(12) | Materials | 379,360 Preferred Stock Warrants | 187 | 528 |
| Powerhouse Dynamics, Inc. (2)(12) | Power Management | 348,838 Preferred Stock Warrants | 33 | 34 |
| Avalanche Technology, Inc. (2)(12) | Semiconductors | 202,602 Preferred Stock Warrants | 101 | 38 |
| Kaminario, Inc. (12) | Semiconductors | 4,800,000 Preferred Stock Warrants | 59 | 97 |
| Luxtera, Inc.(2)(12) | Semiconductors | 3,546,553 Preferred Stock Warrants | 213 | 401 |
| Soraa, Inc. (2)(12) | Semiconductors | 203,616 Preferred Stock Warrants | 80 | 430 |
| Bolt Solutions Inc. (2)(12) | Software | 202,892 Preferred Stock Warrants | 113 | 106 |
| Bridge2 Solutions, Inc. (2)(12) | Software | 125,458 Common Stock Warrants | 432 | 767 |
| BSI Platform Holdings, LLC (2)(12)(13) | Software | 137,500 Preferred Stock Warrants | 19 | 19 |
| Clarabridge, Inc. (12) | Software | 53,486 Preferred Stock Warrants | 14 | 106 |
| Education Elements, Inc. (2)(12) | Software | 238,121 Preferred Stock Warrants | 28 | 30 |
| Lotame Solutions, Inc. (2)(12) | Software | 288,115 Preferred Stock Warrants | 22 | 289 |
| Metricly, Inc. (12) | Software | 41,569 Common Stock Warrants | 48 | _ |
| Riv Data Corp. (2)(12) | Software | 321,428 Preferred Stock Warrants | 12 | 37 |
| ShopKeep.com, Inc. (2)(12) | Software | 193,962 Preferred Stock Warrants | 118 | 117 |
| SIGNiX, Inc. (12) | Software | 133,560 Preferred Stock Warrants | 225 | 36 |

| Skyword, Inc. (12) | Software | 301,056 Preferred Stock Warrants | 48 | 3 |
|--|------------------------|---------------------------------------|--------------|---------------|
| Sys-Tech Solutions, Inc. (2)(12) | Software | 375,000 Preferred Stock Warrants | 242 | 444 |
| Weblinc Corporation (2)(12) | Software | 195,122 Preferred Stock Warrants | 42 | |
| xAd, Inc. (2)(12) | Software | 4,343,350 Preferred Stock Warrants | 177 | 299 |
| Total Non-Affiliate Warrants — T Non-Affiliate Warrants — Cleante | <i>C</i> , | | 4,010 | 7,296 |
| Renmatix, Inc. (2)(12) | Alternative Energy | 53,022 Preferred Stock Warrants | 68 | _ |
| Tigo Energy, Inc. (2)(12) | Energy Efficiency | 804,604 Preferred Stock Warrants | 100 | 113 |
| Total Non-Affiliate Warrants — C | | | 168 | 113 |
| Non-Affiliate Warrants — Healtho | care information and | * * | | |
| LifePrint Group, Inc. (2)(12) | Diagnostics | 49,000 Preferred Stock Warrants | 29 | 2 |
| ProterixBio, Inc. (2)(12) | Diagnostics | 2,676 Common Stock Warrants | 42 | _ |
| Singulex, Inc. (12) | Other Healthcare | 294,231 Preferred Stock Warrants | 44 | 46 |
| Verity Solutions Group, Inc. (12) | Other Healthcare | 300,360 Preferred Stock Warrants | 100 | 67 |
| Watermark Medical, Inc. (2)(12) | Other Healthcare | 27,373 Preferred Stock Warrants | 74 | 63 |
| HealthEdge Software, Inc. (2)(12) | Software | 205,481 Preferred Stock Warrants | 83 | 72 |
| Medsphere Systems Corporation (2)(12) | Software | 7,097,792 Preferred Stock Warrants | 60 | 216 |
| Recondo Technology, Inc. (2)(12) | Software | 556,796 Preferred Stock Warrants | 95 | 215 |
| Total Non-Affiliate Warrants — Hotal Non-Affiliate Warrants | lealthcare information | on and services | 527 6,802 | 681 10,426 |
| Non-Affiliate Other Investments – | -5.7% (8) | | | |
| Espero Pharmaceuticals, Inc. (12) | • • | Royalty Agreement | 5,300 | 4,700 |
| ZetrOZ, Inc. (12) | Medical Device | Royalty Agreement | 179 | 700 |
| Vette Technology, LLC (12) | Data Storage | Royalty Agreement Due 4/18/2019 | 4,183 | 60 |